Nodular sclerosing Hodgkin's disease is characterized by dense collagen fibrosis. Although transforming growth factorbeta (TGF-fl) is an important bifunctional growth factor for fibroblasts and is stored and released by many cells, it requires acidification to pH 2.0-3.0 before it becomes a biologically active growth factor. We show here that the L428 Hodgkin's cell releases a high molecular weight TGF that competes for the TGF-ft cell membrane receptor but not the TGF-a receptor. This growth factor is most active at physiologic pH and is 97% inactivated by acidification. Hodgkin's TGF is also inactivated by proteases and can be preserved by protease inhibitors. The Hodgkin's TGF can be separated from an autocrine growth factor using either column chromatography or electroelution from gels and is shown to have a molecular weight of -350,000. Incubation of the Hodgkin's TGF in SDS releases a 25,000-D protein with reduced biological activity but which cross-reacts with anti-TGF-ft IgG. We propose that L428 nodular sclerosing Hodgkin's disease fibrosis is mediated by a potent high molecular weight TGF-,B which, unlike 8 characterized to date, is secreted in a form most active at physiologic pH.
Introduction
Nodular sclerosing Hodgkin's disease is the most common pathological subtype of Hodgkin's disease and is characterized by dense collagen bands which, in addition to benign cellular proliferation, account for the bulk of the Hodgkin's neoplasm (1, 2) . Attempts to demonstrate malignant properties of the fibroblasts within the sclerosis have proven futile (3) and have led to the hypothesis that the fibroblast proliferation is secondary to diffusible growth factors secreted by adjacent cells, perhaps the malignant Reed-Sternberg cells (3, 4) .
We have previously shown that short-term, partially purified Reed-Sternberg cell cultures secrete a potent growth factor for fibroblasts into the serum-free medium (3) , that the growth factor is secreted in an active form at physiologic pH, that the growth factor does not have the biological properties of IL 1 (4) , and that it produces transformation-like growth of fibroblasts in monolayer and soft agar (3, 4) . To determine the identity of the growth factor we have studied a cell culture, L-428, established from the pleural effusion of a woman with refractory stage IV B nodular sclerosing Hodgkin's disease (5, 6). L-428 Hodgkin's cells resemble fresh uncultured Hodgkin's cells in most aspects studied including surface antigen phenotype, morphology, cytochemistry, and gene rearrangement (5) (6) (7) (8) . Therefore, we propose that observations made of L-428 Hodgkin's cells in vitro may be useful in understanding the pathophysiology of nodular sclerosing Hodgkin's disease.
The transforming growth factor (TGF)' produced by L-428 cells is characterized in this report. This growth factor, although binding to the TGF-f receptor and sharing many biological features of TGF-f3, is unlike TGF-f because it is secreted in an active high molecular weight form. This observation is important, not only because of its relevance to nodular sclerosing Hodgkin's disease, but because it demonstrates that TGF-,3 can be secreted in a form that is active at physiologic pH and is more potent than the tissue extracts and cell products reported to date (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . As well as being an important growth factor in Hodgkin's disease, it is suggested that this form ofTGF-f should be investigated as a possible mediator of benign cell growth in conditions other than Hodgkin's disease.
Methods

Growth factors
Receptor-grade epidermal growth factor (EGF) and '25I-EGF were (b) Preservation ofHodgkin's TGF usingprotease inhibitors. Fresh CM from L-428 cells (serum-free) was prepared using protease inhibitors (5.3 mg% PMSF and 0.3 mg% pepstatin A) that were added at 1, 6, and 24 h. After addition ofthe inhibitors, the CM was dialyzed against serum-free Iscove's medium and tested for TGF-,B activity. This experiment assessed the potential role of endogenous proteases in the activation of Hodgkin's TGF.
(c) PAGE. Using a modification of the Laemmli method (23) Hodgkin's TGF was electrophoresed into 4-30% gels. Biological activity was tested by slicing the gels horizontally and removing the growth factor by electroelution. Molecular weight determination of purified specimens from column chromatography and ion exchange was made using 1% SDS. Gels were fixed in methanol and stained with either Coomassie brilliant blue or silver. Western blotting was performed using nitrocellulose paper and an 18-h transfer at 60 V. A polyclonal affinity-purified rabbit IgG anti-TGF-,B was used to bind Hodgkin's TGF-fl (R & D Systems, Inc., Minneapolis, MN). Staining of bound antibody was performed using a biotinylated anti-rabbit affinity-purified antibody and alkaline phosphate-conjugated avidin.
(d) Column chromatography. Molecular sizing was performed using a 1.6 X 100 cm column packed with a cross-linked agarose gel (Sepharose-CL6B). The linear fractionation range is 1,500-650,000 D. The column was equilibrated in a Tris-saline buffer (100 mM Tris, 200 mM NaCl, 2 mM EDTA, pH 8.0). A selectivity curve was constructed using standard compounds of known molecular mass (thyroglobulin 670 kD, gamma globulin 160 kD, ovalbumin 44 kD, myoglobin 17 kD, cyanocobalamin 1.35 kD). The protein concentration of each column fraction was estimated using an ultraviolet spectrophotometer (OD280). Ion exchange was performed using 1 X 10 cm columns packed with either carboxymethyl (CM)-agarose or DEAE-agarose. Elution was performed using a KC1 gradient (0-0.6 M) in a 50-mM imidazole buffer, pH 7.0. The column was regenerated using 250 mM imidazole. Epithelial cell DNA synthesis inhibition Almost complete inhibition of epithelial cell DNA synthesis could be obtained with picomolar concentrations of platelet TGF-(3 1 or high molecular weight Hodgkin's TGF. The titration curves of purified Hodgkin's TGF and platelet TGF-3 were parallel and overlapping (see Fig. 1 B) .
Receptor binding
The receptor binding assays indicated specific competition of Hodgkin's TGF for the AKR-2B cell TGF-,3 receptor. Using this assay, each L-428 Hodgkin's cell was estimated to produce I fM TGF-fl/d. A titration curve of purified high molecular weight Hodgkin's TGF receptor binding could be approximated to the binding curve obtained with platelet TGF-f (see Fig. 1 C) . There was no evidence of competition for the TGF-a (EGF) receptor.
Northern blots L-428 Hodgkin's cells, when shown to produce TGF-f3 activity, were examined to determine if they expressed mRNA for TGF-f,. Fig. 2 we compared the effect of control medium and L-428 CM on DNA synthesis with the NRK cells at rest in a monolayer (serum free). There was a reduction of DNA synthesis to 15% of the resting serum-free level after 24 h of exposure to Hodgkin's TGF. The data are presented in Table I Tables II and IV) . (c) PAGE. Hodgkin's TGF submitted to PAGE in physiologic conditions allowed elution of two bands of biological activity from slices at 300 and 350 kD (Fig. 4 A) but after exposure to SDS (1%) the high molecular weight bands were no longer visible even with silver staining. A prominent band at 25,000 D was noted that was comparable to an identical band of TGF-j3 obtained from purified platelets (Fig. 5 A) . Testing of eluates from slices of the entire SDS-gel indicated that TGF-fi activity could be found only in the 25,000-D slice (Fig. 5 B) . (Fig. 4 B) .
(e) Ion exchange chromatography. Ion exchange demonstrated binding of Hodgkin's TGF to DEAE-agarose and not to CM-agarose, indicating that the Hodgkin's TGF is a weak acid at physiologic pH. The peak Hodgkin's TGF activity was eluted at 20 mS of electroconductivity.
Discussion
The biological activity of Hodgkin's TGF has been previously reported in the serum-free CM of short-term cultures of partially purified Reed-Sternberg and mononuclear Hodgkin's cells from nodular sclerosis (3, 4) . We studied the L-428 Hodgkin's cell line to determine if L-428 cells produced similar biological activity and to characterize the nature of this TGF.
We report here that L-428 cells express mRNA for TGF-f3 and secrete large amounts of a potent growth factor for fibro- have also shown that Hodgkin's TGF does not compete for the TGF-a (EGF) receptors on the membrane of human diploid fibroblasts.
In contrast to the ubiquitous 25,000-D TGF-f extracted by acid-ethanol from many sources (9, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 25) , we found that the Hodgkin's TGF is secreted as a potent active form at physiologic pH and is almost, but not completely, destroyed by acidification (97%). In addition, there was no evidence that Hodgkin's TGF requires activation by proteases. Hodgkin's TGF is destroyed by exposure to an exogenous protease (trypsin) and is protected by inhibition of endogenous proteases. (A comparison of the properties of Hodgkin's TGF and TGF-,B is presented in Table V.) Partial purification of Hodgkin's TGF supports the concept that Hodgkin's TGF contains the TGF-j molecule, not only because of specific receptor binding, but because a prominent 25,000-D band, identical to purified TGF-fl, appeared after exposure of Hodgkin's TGF to SDS. This band crossreacted with anti-TGF-f, antibody and was eluted from the gel and shown to have TGF-3 biological activity.
The physiologic role of TGF-3 is unclear. Although extensive work has been performed and many in vitro (I 1-20, 25) and some in vivo experiments (26, 27) Although speculative, it appears likely to us that in benign inflammatory reactions and wound healing, fibroblast proliferation is partially mediated by a molecular form of TGF-j3 similar to Hodgkin's TGF rather than the acid-stable low molecular weight form characterized to date (9, 11-20, 25, 26) . The secretion of a physiologically active high molecular weight form of TGF-fl might be a transient feature of nonmalignant cells that may account for the failure to identify the complete growth factor previously.
